Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis

Journal of Immunology

Volumn 163, Issue 8, 1999, Pages 4481-4488

  Kenney, Richard T ^a,e   Sacks, David L ^b   Sypek, Joseph P ^c   Vilela, Luciano ^d   Gam, Albert A ^a   Evans Davis, Kamela ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c PFIZER INC   (United States)

^d Biotechnology Unit   (Brazil)

^e HFM 416 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; RECOMBINANT INTERLEUKIN 12;

ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; IMMUNITY; IMMUNOGENICITY; LEISHMANIA; MONKEY; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SUBCUTANEOUS DRUG ADMINISTRATION; SUBCUTANEOUS NODULE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNITY, ACTIVE; INTERFERON TYPE II; INTERLEUKIN-12; LEISHMANIASIS, CUTANEOUS; MACACA MULATTA; PROTOZOAN VACCINES; VACCINES, SYNTHETIC;

EID: 0032864099     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Nicolle, M. M., and L. Manceau. 1910. Recherches sur le bouton d'Orient: cultures, reproduction expérimentale, immunization. Ann. Inst. Pasteur 24:673.
2. Senekji, H. A., and C. P. Beattie. 1941. Artificial infection and immunization of man with cultures of Leishmania tropica. Trans. R. Soc. Trop. Med. Hyg. 34:415.
3. Guirges, S. Y. 1971. Natural and experimental re-infection of man with Oriental sore. Ann. Trop. Med. Parasitol. 65:197.
4. Sokolova, A. N. 1940. Preventive vaccination with the living parasites of cutaneous leishmaniasis. Trans. Turkmen Cutan-Venereol Inst. Ashkhabad 11:44.
5. Katzenellenbogen, I. 1944. Vaccination against oriental sore: report of results of five hundred and fifty-five inoculations. Arch. Dermat. Syph. 50:239.
6. Naggan, L., A. E. Guilders, and D. Michaeli. 1972. Follow-up study of a vaccination programme against cutaneous leishmaniasis. II. Vaccination with a recently isolated strain of L. tropica from Jericho. Trans. R. Soc. Trop. Med. Hyg. 66:239.
7. Modabber, F. 1989. Experiences with vaccines against cutaneous leishmaniasis: of men and mice. Parasitology 98:S49.
8. Mendonca, S. C., P. M. De Luca, W. Mayrink, T. G. Restom, F. Conceicao-Silva, A. M. Da-Cruz, A. L. Bertho, C. A. Da Costa, O. Genaro, V. P. Toledo, and S. G. Coutinho. 1995. Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis. Am. J. Trop. Med. Hyg. 53:195.
9. Grimaldi, G. Jr. 1995. Meetings on vaccine studies towards the control of leishmaniasis: UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) February 13-22 and April 4-5, 1995. Mem. Inst. Oswaldo Cruz 90:553.
10. Coutinho, S. G., M. P. Oliveira, A. M. Da-Cruz, P. M. De Luca, S. C. Mendonca, A. L. Bertho, L. Soong, and D. McMahon-Pratt. 1996. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Exp. Parasitol. 84:144.
11. Titus, R. G., F. J. Gueiros-Filho, L. A. de Freitas, and S. M. Beverley. 1995. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA 92:10267.
12. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137.
13. Antunes, C. M., W. Mayrink, P. A. Magalhaes, C. A. Costa, M. N. Melo, M. Dias, M. S. Michalick, P. Williams, A. O. Lima, J. B. Vieira, and A. P. M. Schettini. 1986. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int. J. Epidemiol. 15:572.
14. Engers, H. D., R. Bergquist, and F. Modabber. 1996. Progress on vaccines against parasites. Dev. Biol. Stand. 87:73.
15. Armijos, R. X., M. M. Weigel, H. Aviles, R. Maldonado, and J. Racines. 1998. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during 12 months of follow-up. J. Infect. Dis. 177:1352.
16. Howard, J. G., F. Y. Liew, C. Hale, and S. Nicklin. 1984. Prophylactic immunization against experimental leishmaniasis. 11. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes. J. Immunol. 132:450
17. Scott, P., E. Pearce, P. Natovitz, and A. Sher. 1987. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J. Immunol. 139:221.
18. Pirmez, C., M. Yamamura, K. Uyemura, M. Paes-Oliveira, F. Conceicao-Silva, and R. L. Modlin. 1993. Cytokine patterns in the pathogenesis of human leishmaniasis. J. Clin. Invest. 91:1390.
19. Wolf, S. F., D. Sieburth, and J. Sypek. 1994. Interleukin 12: a key modulator of immune function. Stern Cells 12:154.
20. Sypek, J. P., C. L. Chung, S. E. Mayor, J. M. Subramanyam, S. J. Goldman, D. S. Sieburth, S. F. Wolf, and R. G. Schaub. 1993. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1797.
21. Heinzel, F. P., D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, and M. K. Gately. 1993. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177:1505.
22. Mattner, F., J. Magram, J. Ferrante, P. Launois, K. Di Padova, R. Behin, M. K. Gately, J. A. Louis, and G. Alber. 1996. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 26:1553.
23. Afonso, L. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235.
24. Mougneau, E., F. Altare, A. E. Wakil, S. Zheng, T. Coppola, Z. E. Wang, R. Waldmann, R. M. Locksley, and N. Glaichenhaus. 1995. Expression cloning of a protective Leishmania antigen. Science 268:563.
25. Gurunathan, S., C. Prussin, D. L. Sacks, and R. A. Seder. 1998. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4:1409.
26. Jankovic, D., P. Caspar, M. Zweig, M. Garcia-Moll, S. D. Showalter, F. R. Vogel, and A. Sher. 1997. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J. Immunol. 159:2409.
27. Lawyer, P. G., J. I. Githure, C. O. Anjili, J. O. Olobo, D. K. Koech, and G. D. Reid. 1990. Experimental transmission of Leishmania major to vervet monkeys (Cercopithecus aethiops) by bites of Phlebotomus duboscqi (Diptera: Psychodidae). Trans. R. Soc. Trop. Med. Hyg. 84:229.
28. Amaral, V. F., V. A. Ransatto, F. Conceicao-Silva, E. Molinaro, V. Ferreira, S. G. Coutinho, D. McMahon-Pratt, and G. Grimaldi, Jr. 1996. Leishmania amazonensis: the Asian rhesus macaques (Macaca mulatta) as an experimental model for study of cutaneous leishmaniasis. Exp. Parasitol. 82:34.
29. Githure, J. I., G. D. Reid, A. A. Binhazim, C. O. Anjili, A. M. Shatry, and L. D. Hendricks. 1987. Leishmania major: the suitability of East African non-human primates as animal models for cutaneous leishmaniasis. Exp. Parasitol. 64:438.
30. Olobo, J. O., C. O. Anjili, M. M. Gicheru, P. A. Mbati, T. M. Kariuki, J. I. Githure, D. K. Koech, and W. R. McMaster. 1995. Vaccination of vervet monkeys against cutaneous leishmaniasis using recombinant Leishmania "major surface glycoprotein" (gp63). Vet. Parasitol. 60:199.
31. Dube, A., P. Sharma, J. K. Srivastava, A. Misra, S. Naik, and J. C. Katiyar. 1998. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 116:219.
32. Mayrink, W., P. Williams, C. A. da Costa, P. A. Magalhaes, M. N. Melo, M. Dias, A. Oliveira Lima, M. S. Michalick, E. Ferreira Carvalho, G. C. Barros, et al. 1985. An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil. Ann. Trop. Med. Parasitol. 79:259.
33. Genaro, O., V. P. de Toledo, C. A. da Costa, M. V. Hermeto, L. C. Afonso, and W. Mayrink, 1996. Vaccine for prophylaxis and immunotherapy, Brazil. Clin. Dermatol. 14:503.
34. Villinger, F., S. S. Brar, A. Mayne, N. Chikkala, and A. A. Ansari. 1995. Comparative sequence analysis of cytokine genes from human and nonhuman primates. J. Immunol. 155:3946.
35. Coutinho, S. G., A. M. Da-Cruz, A. L. Bertho, M. A. Santiago, and P. De-Luca. 1998. Immunologic patterns associated with cure in human American cutaneous leishmaniasis. Braz. J. Med. Biol. Res. 31:139.
36. Castes, M., J. Blackwell, D. Trujillo, S. Formica, M. Cabrera, G. Zorrilla, A. Rodas, P. L. Castellanos, and J. Convit. 1994. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I. Skin-test reactivity, T-cell proliferation and interferon-γ production. Vaccine 12:1041.
37. Stenger, S., N. Donhauser, H. Thuring, M. Rollinghoff, and C. Bogdan. 1996. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183:1501.
38. Schubach, A., M. C. Marzochi, T. Cuzzi-Maya, A. V. Oliveira, M. L. Araujo, A. L. Oliveira, R. S. Pacheco, H. Momen, F. Conceicao-Silva, S. G. Coutinho, and K. B. Marzochi. 1998. Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am. J. Trop. Med. Hyg. 58:824.
39. Bahar, K., Y. Dowlati, B. Shidani, M. H. Alimohammadian, A. Khamesipour, S. Ehsasi, R. Hashemi-Fesharki, S. Ale-Agha, and F. Modabber. 1996. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin. Dermatol. 14:489.
40. Sharifi, I., A. R. FeKri, M. Aflatonian, A. Khamesipour, A. Nadim, M. A. Mousavi, A. Z. Momeni, Y. Dowlati, T. Godal, F. Zicker, P. G. Smith, and F. Modabber. 1998. Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351:1540.
41. Modabber, F. 1995. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 89(Suppl. 1):83.
42. Liew, F. Y., C. Hale, and J. G. Howard. 1985. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J. Immunol. 135:2095.
43. Reiner, S. L., Z. E. Wang, F. Hatam, P. Scott, and R. M. Locksley. 1993. TH1 and TH2 cell antigen receptors in experimental leishmaniasis. Science 259:1457.
44. Scott, P. 1991. IFN-γ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147:3149.
45. White, R. G., A. H. Coons, and J. M. Connolly. 1955. Studies on antibody production. III. The alum granuloma. J. Exp. Med. 102:73.
46. Gupta, R. K., E. H. Relyveld, E. B. Lindblad, B. Bizzini, S. Ben-Efraim, and C. K. Gupta. 1993. Adjuvants: a balance between toxicity and adjuvanticity. Vaccine 11:293.
47. Slater, D. N., J. C. Underwood, T. E. Durrant, T. Gray, and I. P. Hopper. 1982. Aluminium hydroxide granulomas: light and electron microscopic studies. Br. J. Dermatol. 107:103.
48. Ahlers, J. D., N. Dunlop, D. W. Ailing, P. L. Nara, and J. A. Berzofsky. 1997. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-α synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J. Immunol. 158:3947.
49. Titus, R. G., G. C. Lima, H. D. Engers, and J. A. Louis. 1984. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity. J. Immunol. 133:1594.
50. Liew, F. Y., A. Singleton, E. Cillari, and J. G. Howard. 1985. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection. J. Immunol. 135:2102.